NYSEAMERICAN:PHGE BiomX (PHGE) Stock Price, News & Analysis $0.14 0.00 (-0.28%) As of 09/3/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About BiomX Stock (NYSEAMERICAN:PHGE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BiomX alerts:Sign Up Key Stats Today's Range$0.13▼$0.1550-Day Range$0.13▼$0.4052-Week Range$0.12▼$12.29Volume2.49 million shsAverage Volume1.46 million shsMarket Capitalization$3.80 millionP/E RatioN/ADividend YieldN/APrice Target$26.00Consensus RatingHold Company Overview BiomX Inc. is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases. The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis. Preclinical studies have demonstrated the ability of BiomX’s phage preparations to reduce targeted bacterial populations implicated in inflammation and disease progression. Advanced product characterization and manufacturing processes support both oral and topical delivery formats, positioning BiomX to advance multiple candidates through regulatory pathways. Founded in 2016 as a spin-out from MIGAL – Galilee Research Institute, BiomX is headquartered in Rehovot, Israel, with a U.S. presence in Cambridge, Massachusetts. The company conducts clinical trials across North America and Europe, collaborating with academic medical centers and contract research organizations. Since its initial public listing on the NYSE American exchange under the ticker PHGE, BiomX has expanded its leadership team to include executives with deep expertise in phage biology, clinical development and biomanufacturing. The company’s research and development efforts are overseen by CEO Eliora Ron, who guides strategic initiatives to translate microbiome science into targeted, next-generation therapies.AI Generated. May Contain Errors. Read More BiomX Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScorePHGE MarketRank™: BiomX scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingBiomX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Upside PotentialBiomX has a consensus price target of $26.00, representing about 18,197.0% upside from its current price of $0.14.Amount of Analyst CoverageBiomX has received no research coverage in the past 90 days.Read more about BiomX's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for BiomX are expected to decrease in the coming year, from ($5.85) to ($6.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiomX is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiomX is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomX has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BiomX's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.89% of the float of BiomX has been sold short.Short Interest Ratio / Days to CoverBiomX has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BiomX has recently decreased by 29.39%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomX does not currently pay a dividend.Dividend GrowthBiomX does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.36 News SentimentBiomX has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for BiomX this week, compared to 2 articles on an average week. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BiomX insiders have not sold or bought any company stock.Percentage Held by Insiders0.23% of the stock of BiomX is held by insiders.Percentage Held by Institutions40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BiomX's insider trading history. Receive PHGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHGE Stock News HeadlinesBiomX To Rebrand As Tessera Defense; Adopts HLSQ Ticker;Stock UpSeptember 1 at 12:50 PM | rttnews.comBiomX Inc. to Rename Itself Tessera Defense and Homeland Security Inc. and Change NYSE American Ticker to HLSQSeptember 1 at 9:31 AM | quiverquant.comQMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation. | Paradigm Press (Ad)BiomX Inc. to Become Tessera Defense and Homeland Security Inc.September 1 at 9:25 AM | globenewswire.comBiomX Shares Scheduled to Reverse Split on Wednesday, September 9th (NYSEAMERICAN:PHGE)September 1 at 1:26 AM | americanbankingnews.comBiomX Shareholders Approve One-for-Ten Reverse SplitAugust 28, 2026 | tipranks.comBiomX Shareholders Approve Mandragola Deal and Reverse SplitAugust 25, 2026 | tipranks.comBiomX delays quarterly filing amid acquisitions and auditAugust 14, 2026 | tipranks.comSee More Headlines PHGE Stock Analysis - Frequently Asked Questions How have PHGE shares performed this year? BiomX's stock was trading at $1.87 on January 1st, 2026. Since then, PHGE stock has decreased by 92.4% and is now trading at $0.1421. How were BiomX's earnings last quarter? BiomX Inc. (NYSEAMERICAN:PHGE) announced its earnings results on Wednesday, August, 19th. The company reported ($0.37) EPS for the quarter. The firm earned $0.33 million during the quarter. When did BiomX's stock split? Shares of BiomX reverse split on Tuesday, November 25th 2025.The 1-19 reverse split was announced on Friday, November 14th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of BiomX? Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BiomX own? Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Moderna (MRNA), T2 Biosystems (TTOO), Chegg (CHGG), Aldeyra Therapeutics (ALDX), Nokia (NOK), Avino Silver & Gold Mines (ASM) and Anavex Life Sciences (AVXL). Company Calendar Last Earnings8/19/2026Today9/04/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PHGE's financial health is in the Yellow zone, according to TradeSmith. PHGE has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:PHGE Previous SymbolNYSEMKT:PHGE CIK1739174 Webwww.biomx.com Phone972-7-2394-2377FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for BiomX$26.00 High Price Target$26.00 Low Price Target$26.00 Potential Upside/Downside+18,197.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.20 million Net MarginsN/A Pretax Margin-13,700.30% Return on EquityN/A Return on Assets-165.38% Debt Debt-to-Equity Ratio0.02 Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book0.34Miscellaneous Outstanding Shares26,720,000Free Float26,663,000Market Cap$3.80 million OptionableN/A Beta1.33 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSEAMERICAN:PHGE) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredAre you leaving Social Security money on the table?Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....Money Pickle | SponsoredHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiomX Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BiomX With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
